Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study

Anna Almén-Christensson; Mats Hammar; Lotta Lindh-Åstrand; Anne-Marie Landtblom; Jan Brynhildsen

doi:10.1016/j.fertnstert.2011.05.089

Prevention of menstrual migraine with perimenstrual transdermal 17-β-estradiol: a randomized, placebo-controlled, double-blind crossover study

Fertil Steril. 2011 Aug;96(2):498-500.e1. doi: 10.1016/j.fertnstert.2011.05.089. Epub 2011 Jun 24.

Authors

Anna Almén-Christensson¹, Mats Hammar, Lotta Lindh-Åstrand, Anne-Marie Landtblom, Jan Brynhildsen

Affiliation

¹ Division of Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.

PMID: 21704313
DOI: 10.1016/j.fertnstert.2011.05.089

Abstract

The effect of treatment with percutaneous E(2) (100 μg/24 h) during 2 weeks perimenstrually on the number and severity of menstrual migraine attacks was studied in 27 women in a randomized, placebo-controlled, double-blind, crossover trial. We were not able to demonstrate any difference between E(2) supplementation and placebo on the number or severity of migraine attacks, but both regimens showed significant effects compared with before treatment. CLINICAL TRIAL IDENTIFICATION NUMBER: NCT00204074.

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Administration, Cutaneous
Adult
Cross-Over Studies
Double-Blind Method
Drug Administration Schedule
Estradiol / administration & dosage*
Female
Humans
Menstrual Cycle*
Migraine Disorders / diagnosis
Migraine Disorders / etiology
Migraine Disorders / prevention & control*
Placebo Effect
Severity of Illness Index
Sweden
Time Factors
Transdermal Patch
Treatment Outcome

Substances

Estradiol

Associated data

ClinicalTrials.gov/NCT00204074